PARADIGM Trial Shows Venetoclax-Azacitidine Superior to Intensive Chemotherapy in Newly Diagnosed AML
核心洞察
The phase 2 PARADIGM trial demonstrated that venetoclax-azacitidine combination therapy achieved superior overall response rates compared to intensive chemotherapy in newly diagnosed AML (搜索) patients eligible for intensive treatment.
Patients receiving venetoclax-azacitidine experienced significantly better quality of life, reduced hospital stays, and lower toxicity while maintaining higher transplant rates compared to those on intensive chemotherapy.
The study excluded patients with potentially curable disease subtypes including core binding factor leukemia, FLT3 (搜索) mutations, and NPM1 (搜索) mutations in patients under 60 years old.
The phase 2 PARADIGM trial has delivered potentially practice-changing results for acute myeloid leukemia (搜索) (AML (搜索)) treatment, demonstrating that a venetoclax-azacitidine combination outperformed intensive chemotherapy in newly diagnosed patients eligible for aggressive treatment. The findings, presented at the 2025 ASH Annual Meeting, challenge decades of established treatment protocols.
Study Design and Patient Population
The multicenter, randomized PARADIGM trial (NCT04801797) enrolled approximately 85 patients per arm across nine major academic centers in the United States. Led by Amir Fathi, MD, from Massachusetts General Hospital, the investigator-initiated study compared venetoclax with azacitidine against intensive chemotherapy using either 7+3 or CPX-351 (liposomal daunorubicin and cytarabine).
The trial specifically excluded patients with potentially curable disease subtypes to focus on those with adverse-risk genotypes. Exclusions included patients with core binding factor leukemia (translocation 8;21 and inversion 16), FLT3 (搜索) mutations, and NPM1 (搜索) mutations in patients younger than 60 years of age. Patients 60 years and older with NPM1 mutations were eligible due to their poorer prognosis with intensive chemotherapy.
Primary Efficacy Outcomes
The study met its primary endpoint, with overall response rates statistically favoring the venetoclax-azacitidine combination. Complete response rates, while numerically higher in the venetoclax-azacitidine arm, showed no statistically significant difference between treatment groups.
"The [overall response rate] statistically favored venetoclax/azacitidine," noted Harry P. Erba, MD, PhD, professor of medicine at Duke Cancer Institute. "The complete response rates were a little closer [to each other], and [the difference was] not statistically different but still numerically greater with venetoclax/azacitidine."
Safety and Quality of Life Advantages
Multiple safety parameters favored the venetoclax-azacitidine regimen over intensive chemotherapy. Patients receiving the combination therapy experienced substantially reduced hospital days and intensive care unit time during initial hospitalization. The study also documented improved quality of life metrics, including lower symptom burden and reduced depression symptoms during treatment.
"The toxicity of a venetoclax/azacitidine regimen is less than that of intensive chemotherapy, so you may allow more patients to get to the transplant," Erba explained. The disparity in transplant rates between the two groups supported this hypothesis, with more patients in the venetoclax-azacitidine arm proceeding to transplantation.
Clinical Implications for AML Treatment
The results represent a potential paradigm shift in AML (搜索) management, particularly for patients with adverse-risk disease. Eunice S. Wang, MD, professor of oncology at Roswell Park Comprehensive Cancer Center, emphasized the study's significance: "This has the potential to change how we treat these patients. Moving forward, adverse-risk patients, regardless of their fitness, may end up receiving a venetoclax/azacitidine-based regimen."
Most patients in the trial had adverse-risk disease according to European LeukemiaNet 2022 risk classification criteria, meaning they typically experience poor outcomes with intensive chemotherapy. The venetoclax-azacitidine combination, previously reserved for older, unfit patients aged 75 and above, demonstrated superior efficacy in this younger, fit population.
Expanding Venetoclax-Based Combinations
The ASH meeting also featured advances in triplet therapies building on the venetoclax-azacitidine backbone. The phase 1/2 VICEROY trial (NCT05520567) evaluated adding gilteritinib, a FLT3 (搜索) inhibitor, to venetoclax-azacitidine in newly diagnosed FLT3-mutant AML (搜索) patients. Results showed enhanced outcomes without markedly increased toxicity.
Similarly, the phase 1 KOMET-007 trial (NCT05735184) investigated ziftomenib, a newly approved menin (搜索) inhibitor, combined with venetoclax-azacitidine in NPM1 (搜索)-mutant disease. The combination achieved high overall response and composite complete response rates with no increased toxicity, QTc prolongation, or differentiation syndrome.
"These 2 abstracts have the potential to make triplet venetoclax/azacitidine-based therapy the [standard of care] for subsets of AML (搜索), which harkens to a new age of precision medicine for the treatment of patients with AML," Wang noted.
Future Directions and Considerations
While the PARADIGM results are promising, experts acknowledge that survival data will be crucial for full evaluation. The study's focus on adverse-risk patients who don't appear to have disease curable with standard intensive chemotherapy represents a targeted approach to treatment selection.
The findings are expected to influence ongoing clinical trial designs and may reshape treatment algorithms for newly diagnosed AML (搜索) patients. As Erba concluded, "I can't imagine a more impactful study in reality. [However], we will need to see the survival data."